Loading clinical trials...
Loading clinical trials...
This study is conducted in Japan. The aim of this registry study is to observe the use of single dose and multi-dose use of eptacog alpha (NovoSeven®) and to compare short-term outcomes, including eff...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novo Nordisk A/S
NCT02141074 · Congenital Bleeding Disorder, Haemophilia B
NCT02137850 · Congenital Bleeding Disorder, Haemophilia A
NCT05878938 · Haemophilia A, Haemophilia A With Inhibitors
NCT03075670 · Congenital Bleeding Disorder, Haemophilia B
NCT03179748 · Congenital Bleeding Disorder, Haemophilia A
Novo Nordisk Investigational Site
Tokyo
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions